Table 1.
Characteristic | CVD
|
BCT
|
||
---|---|---|---|---|
No. of Patients | % | No. of Patients | % | |
No. of patients | 195 | 200 | ||
Male sex | 147 | 75 | 133 | 67 |
Age | ||||
Median | 50.5 | 50.7 | ||
Range | 19.5-80.4 | 21.0-78.5 | ||
ECOG performance status | ||||
0 | 128 | 66 | 130 | 65 |
1 | 67 | 34 | 70 | 35 |
Prior interferon therapy | ||||
Yes | 74 | 38 | 81 | 40 |
No | 121 | 62 | 140 | 60 |
No. of metastatic sites | ||||
1 | 46 | 24 | 47 | 24 |
2-3 | 113 | 58 | 111 | 55 |
≥ 4 | 36 | 18 | 42 | 21 |
AJCC stage | ||||
M1a | 23 | 12 | 15 | 8 |
M1b | 26 | 14 | 34 | 18 |
M1c | 141 | 74 | 144 | 74 |
Serum LDH | ||||
Normal | 126 | 65 | 122 | 61 |
Above normal | 69 | 35 | 78 | 39 |
Prior therapy | ||||
Radiation | 28 | 15 | 23 | 12 |
Other immunotherapy | 9 | 5 | 5 | 43 |
Abbreviations: CVD, cisplatin, vinblastine, dacarbazine; BCT, biochemotherapy; ECOG, Eastern Cooperative Oncology; AJCC, American Joint Committee on Cancer; LDH, lactate dehydrogenase.